Michael Heffernan is a successful biopharmaceutical entrepreneur with over 30 years of experience in building and leading development stage and commercial companies. He is a co-founder and Chairman/CEO of Avenge Bio, Inc. He is also the Founder and Chairman of Collegium Pharmaceutical (COLL), a company focused on developing and commercializing products for the treatment of pain and related disorders. He previously served as Collegium’s President and CEO from company’s inception until June 2018.

 

Mr. Heffernan is an advisor, investor and board member of numerous public and private biopharmaceutical companies. He currently is a member of the board of directors of Biohaven (BHVN), Collegium (COLL), Trevi (TRVI), and Synlogic (SYBX). Mr. Heffernan has also held previous positions as Chairman/CEO of Onset Dermatologics, a commercial stage dermatology company that he founded and spun out of Collegium to create PreCision Dermatology (acquired by Valeant). He was co-founder and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization (acquired by PhyMatrix Corp). Mr. Heffernan began his career at Eli Lilly and Company where he served in numerous sales and marketing roles.

 

Mr. Heffernan was named E&Y Entrepreneur of the Year, Northeast Regional Winner in 2016. He is a registered pharmacist and earned his B.S. Degree in Pharmacy from the University of Connecticut.